Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mizuho Financial Group Inc. Sponosred ADR (Japan) (MFG) vs Dr. Reddy's Laboratories Ltd Common Stock (RDY) Price & Performance

Mizuho Financial Group Inc. Sponosred ADR (Japan)Trade
Dr. Reddy's Laboratories Ltd Common StockTrade

Price performance (Past 24H)

Key statistics

Mizuho Financial Group Inc. Sponosred ADR (Japan) vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? Mizuho Financial Group Inc. Sponosred ADR (Japan) trades at $9.99 (market cap $127.56B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.78B). The key difference: Mizuho Financial Group Inc. Sponosred ADR (Japan) is far larger — about 11.8× Dr. Reddy's Laboratories Ltd Common Stock's market cap, and Mizuho Financial Group Inc. Sponosred ADR (Japan) pays the higher dividend (1.73%). Which is the better fit depends on your goals — on Pluang, investors hold Mizuho Financial Group Inc. Sponosred ADR (Japan) for 6 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.

MFGRDY
Market Cap
$127.56B$10.78B
Volume
2,374,2522,724,343
Sector
FinancialsHealth
52-Week High
$11.45$15.38
52-Week Low
$6.23$11.38
Typical Hold Time
6 Days0 Days
Enterprise Value
$34.95T$10.68B
Dividend Yield
1.73%0.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mizuho Financial Group Inc. Sponosred ADR (Japan)

Mizuho Financial Group (MFG) trades at $10.60, up slightly by 0.09% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.22 exceeding the $0.17 estimate. Revenue grew to $3.65T in 2025, with a net income margin of 30.42% and a P/E ratio of 14.96, indicating reasonable valuation. Recent news highlights institutional stake adjustments and positive CRA ratings.

MFG presents a mixed outlook; earnings momentum and solid profitability support upside, but bearish technicals and analyst caution (60% hold rating) suggest near-term pressure. Key risks include declining cash flow trends and rising debt-to-asset ratio, while institutional interest and dividend growth potential offer opportunities for long-term investors.

Dr. Reddy's Laboratories Ltd Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MFG

No sentiment data available yet.

RDY
100% Buy0% Sell
Avg holding period · 0 Days

About Mizuho Financial Group Inc. Sponosred ADR (Japan)

Mizuho Financial Group is a Japanese financial services company offering banking, trust, securities, and asset management services. It serves retail, corporate, and institutional clients globally.

Read more on MFG →

About Dr. Reddy's Laboratories Ltd Common Stock

Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.

Read more on RDY →